All News
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn
Dr. John Cush RheumNow ( View Tweet)
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush RheumNow ( View Tweet)
Systemic Score in AOSD to Predict Life-threatening Complications
Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan synovialjoints ( View Tweet)
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
#Behcet’s #syndrome is increasing in the UK
? ⬆️ Detection
? Changing population demographics
? Other reasons
Poster discussion POS0258
#EULAR2024 @RheumNow @eular_org
@Pr1yankaC https://t.co/SEzmJnFMhM
Janet Pope Janetbirdope ( View Tweet)
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 !
Amazing pictures to explain cellular level pathophysiology!
Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE
Bella Mehta bella_mehta ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Bella Mehta bella_mehta ( View Tweet)
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Links:
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Links:
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
d
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb
Dr. John Cush RheumNow ( View Tweet)
Cutoffs for sJADAS10
An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the sJADAS10, a disease activity measure distinguish patients with ID, MiDA, MoDA, HDA.
https://t.co/A0kIqiOWFE https://t.co/zShqs781W1
Dr. John Cush RheumNow ( View Tweet)